Results 51 to 60 of about 88,666 (249)

A New Case of dic(1;15)(p11;p11) in AML M1: Apropos of a Case and a Review of the Literature

Case Reports in Genetics, 2013
Acute myelogenous leukemia (AML) develops as the consequence of a series of genetic changes in a hematopoietic precursor cell. Specific cytogenetic abnormalities have been identified by karyotype analysis in AML. One of the rare chromosomal abnormalities
Deniz Gören Şahin, Beyhan Durak, Eren Gündüz, Sevilhan Artan, Olga Meltem Akay   +4 more
doaj   +1 more source

Pathogenesis of chronic myelogenous leukemia

Haematologica, 1994
n ...
G Bergamaschi, V Rosti
doaj   +4 more sources

Nanomaterials Trigger Functional Anti‐Tumoral Responses in Primary Human Immune Cells

Advanced Science, EarlyView.
Nanoparticles are used to improve immunomodulatory therapies, but the impact of drug‐free nanomaterials on the immune system remains unknown. Screening common biomedical nanoparticles (NPs) reveals that PLGA NPs enhanced NK cell anti‐tumoral activity and transcriptional activation in human NK and pan T cells.
Vincent Mittelheisser, Olivier Lefebvre, Mainak Banerjee, Shayamita Ghosh, Amandine Dupas, Marie‐Charlotte Diringer, Juliette Blumberger, Louis Bochler, Sébastien Harlepp, Annabel Larnicol, Angélique Pichot, Tristan Stemmelen, Anne Molitor, Chloé Moritz, Christine Carapito, Raphaël Carapito, Loïc J. Charbonnière, François Lux, Olivier Tillement, Jacky G. Goetz, Alexandre Detappe   +20 more
wiley   +1 more source

Chloroma of the testis in a patient with a history of acute myeloid leukemia

Journal of Research in Medical Sciences, 2017
Chloroma, or granulocytic sarcoma, is a rare extramedullary solid hematologic cancer, found concomitant with acute myeloid leukemia. It is infrequently associated with other myeloproliferative disorders or chronic myelogenous leukemia.
Mohammad Hossein Sanei, Matin Shariati
doaj   +1 more source

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]

, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem, Abdul Qayyum, Abid Jamil, Abid Taj, Ahmad Khalid, Ammara Tahir, Ijaz Shah, Mahwish Khan, Mubashar Naqvi, Mudassar Iqbal, Muhammad Abbad, Muhammad Ferhan, Muhammad Khalid, Najeeb ur-Rehman, Riaz ul-Haq, Shahid Baig, Tanveer Akhtar, Tariq Gill, Weng Qin, Zafar Iqbal   +19 more
core   +1 more source

Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. [PDF]

, 2013
The aim of supportive autografting is to reduce the side effects from stem cell transplantation and avoid procedure-related health disadvantages for patients at the lowest possible cost and resource expenditure.
Campioni, Dc, Cuneo, A, Farge, D, Fiamenghi, C, Fruehauf, S, Hellmann, A, Johnsen, He, Knopińska, W, Lanza, F, Madrigal, A, Milone, G, Mohty, M, Passweg, J, Petriz, J, Quality Assessment of Haematopoietic Stem Cell Grafting Committee of European Blood and Marrow Transplantation Society, Ruuto, T, Spedini, P, Swierkowska-Czeneszew, M, Wahlin, A, Walewski, J   +19 more
core   +1 more source

Pulmonary Arterial Hypertension Onset in an Adult Woman With a TBX4 Likely Pathogenic Variant Following Imatinib Administration: A Case Report

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The TBX4 gene has a critical importance in the development of the lower limbs and lungs. Pathogenic variants in this gene are associated with a variable spectrum of skeletal anomalies of the lower limb and pneumological manifestations, with dominant or recessive inheritance.
Simone Carbonera, Laura Scelsi, Alessandra Greco, Sandra Schirinzi, Annalisa Turco, Antonella Casella, Marta Carboni, Gaia Visani, Mauro Acquaro, Stefano Ghio, Silvia Kalantari, Enza Maria Valente, Fabio Sirchia   +12 more
wiley   +1 more source

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib

Clinical Case Reports, 2022
Patients with chronic myelogenous leukemia (CML) harboring the T315I mutation who progress to blast phase CML while on ponatinib may be successfully treated with asciminib monotherapy following induction therapy with cytotoxic chemotherapy.
Sarah Tomassetti, Jennifer Lee, Xin Qing
doaj   +1 more source

Myelodysplasia in a psoriasis patient receiving etanercept : Cause or coincidence? [PDF]

, 2018
Peer reviewedFinal Accepted ...
Ayoub, Othman Hadi, Dawoud, Dalia M, Dawoud, Noha Mohammed, Essa, Enas Said   +3 more
core   +3 more sources

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source